U.S., May 29 -- ClinicalTrials.gov registry received information related to the study (NCT07612267) titled 'A Study to Measure Mirikizumab Levels in Breast Milk of Lactating Participants Receiving Mirikizumab Therapeutically for an Approved Indication' on May 21.
Brief Summary: The main purpose of this study is to assess the amount of mirikizumab in breast milk in women who are breastfeeding who are receiving stable maintenance doses of mirikizumab for an approved indication.
Participation in this study could last up to 94 days, including screening and follow-up period.
Study Start Date: June, 2026
Study Type: INTERVENTIONAL
Condition:
Lactation
Inflammatory Bowel Disease
Intervention:
DRUG: Mirikizumab
Administered SC
Recruitment...